NV Medtech has filed a notice of an exempt offering of securities to raise $20,890,293.00 in New Funding.

July 23, 2026 Craig Etkin

According to filings with the U.S. Securities and Exchange Commission, NV Medtech is raising up to $20,890,293.00 in new funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.

About NV Medtech
There are almost 500,000 deaths worldwide each year caused by brain aneurysms, and half the victims are younger than 50. An estimated 1 in 50 people has a brain aneurysm which can lead to a devastating stroke. One out of three brain aneurysm ruptures are fatal. Flow diversion is a minimally invasive treatment option for brain aneurysms. The TUBE flow diverter membrane creates rapid aneurysm occlusion and an ideal scaffold for new tissue growth across the neck of a brain aneurysm, allowing the aneurysm to heal. The TUBE design offers important advantages over previous Flow Diverters: the highest surface coverage for rapid blood flow reduction into the aneurysm, the highest pore density for healthy endothelial growth across the neck, the least metal in our implant design for ease of delivery, and a heparin surface modification to reduce device thrombogenicity.

To learn more, visit https://www.nvmedtech.net/
LinkedIn: https://www.linkedin.com/company/nv-medtech/

Contact:
George Wallace, Chief Executive Officer
https://www.linkedin.com/in/george-wallace-09387612/